NASDAQ$DNLI
Denali Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third quarter and provided business highlights.
Denali Therapeutics reported its Q3 2024 financial results, highlighting progress in its Transport Vehicle (TV)-enabled portfolio, particularly the Enzyme TV (ETV) franchise with tividenofusp alfa for MPS II, and advancements in the DNL126 study for MPS IIIA.
- On track to file for accelerated approval of tividenofusp alfa in MPS II in early 2025 after a successful meeting with the FDA in the third quarter.
- Preliminary data from Phase 1/2 study of DNL126 in MPS IIIA demonstrate a robust reduction from baseline in CSF heparan sulfate levels, including normalization.
- Study of DNL126 in MPS IIIA was expanded to support a potential accelerated path.
- Preclinical publication on oligonucleotide TV (OTV) technology demonstrates broad and deep brain biodistribution of oligonucleotides.
Headline financials
Revenue & EPS history
Denali Therapeutics · Revenue · Quarterly
$0
Forward guidance
Denali anticipates an increase of approximately 5-10% compared to 2023 cash operating expenses. This updated guidance is associated with increased activities to support filing of a BLA in early 2025 and commercial readiness for tividenofusp alfa in MPS II, and to accelerate the development of additional therapeutic programs in Denali's TV platform portfolio.
Tailwinds
- Increased activities to support filing of a BLA in early 2025
- Commercial readiness for tividenofusp alfa in MPS II
- Accelerated development of additional therapeutic programs in Denali's TV platform portfolio
- Advancing OTV:MAPT, targeting tau for Alzheimer’s disease, and OTV:SNCA, targeting alpha-synuclein for Parkinson’s disease, in the investigational new drug (IND)-enabling stage of development.
- Plans to advance a TfR-targeting ATV:Abeta molecule as well as a CD98hc-targeting ATV:Abeta molecule into development for Alzheimer's disease.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.3%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+1.3%
Avg return
30 days after
44%
14 / 32 earnings
Positive
+19.7%
Q4 2023
Best reaction
-13.7%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -1.0% | -4.9% | -15.2% | |
| Q3 2025 | -3.2% | +18.1% | +34.0% | |
| Q1 2025 | +1.0% | -0.9% | +6.1% | |
| Q4 2024 | -1.5% | -15.6% | -21.8% | |
| Q3 2024 | +7.1% | +14.2% | -10.0% | |
| Q2 2024 | -10.3% | -9.7% | +0.3% | |
| Q1 2024 | +10.3% | +6.8% | +24.3% | |
| Q4 2023 | +19.7% | +23.5% | +21.5% | |
| Q3 2023 | -2.7% | -21.8% | -9.7% | |
| Q2 2023 | -5.2% | -7.6% | -7.3% | |
| Q1 2023 | +3.0% | +5.4% | +16.1% | |
| Q4 2022 | +4.8% | +7.3% | -10.9% | |
| Q3 2022 | -7.8% | -10.3% | +6.2% | |
| Q2 2022 | +4.6% | +6.6% | -17.5% | |
| Q1 2022 | -13.7% | -14.0% | -8.5% | |
| Q4 2021 | -2.8% | -7.8% | -1.9% | |
| Q3 2021 | +3.5% | -0.4% | -19.9% | |
| Q2 2021 | +3.5% | +4.6% | +6.6% | |
| Q1 2021 | -8.0% | -10.2% | +5.5% | |
| Q4 2020 | +7.5% | -5.8% | -17.2% | |
| Q3 2020 | +5.2% | +16.3% | +40.8% | |
| Q2 2020 | +6.1% | -5.4% | -2.5% | |
| Q1 2020 | -5.5% | -5.7% | +2.6% | |
| Q4 2019 | -8.6% | -10.0% | -12.5% | |
| Q3 2019 | -6.1% | -10.1% | +10.5% | |
| Q2 2019 | +0.6% | +5.4% | -4.2% | |
| Q1 2019 | -4.8% | -11.4% | -18.9% | |
| Q4 2018 | +11.7% | +12.0% | +26.4% | |
| Q3 2018 | -4.0% | -0.6% | +12.7% | |
| Q2 2018 | -0.5% | -0.7% | +17.0% | |
| Q4 2017 | -4.8% | -5.1% | +2.2% | |
| Q1 2018 | -8.8% | -8.0% | -12.4% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro